Protara Therapeutics, Inc. (Nasdaq: TARA) announced promising results from its Phase 2 ADVANCED-2 trial, sending its stock soaring 116%. The trial evaluated TARA-002, the company’s… [Read More]
December 04, 2024
Stoke Therapeutics Wins FDA Breakthrough Therapy Designation for Dravet Syndrome Treatment
Stoke Therapeutics (Nasdaq: STOK) announced that its investigational therapy, zorevunersen, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the… [Read More]
December 03, 2024
Applied Therapeutics Charts Path Forward After FDA Setback, Eyes European Approval and Pipeline Expansion
Applied Therapeutics (NASDAQ: APLT) received a warning letter from the FDA concerning its study of govorestat, a drug intended to treat the rare genetic disease… [Read More]
Janux Therapeutics (NASDAQ: JANX) reported groundbreaking results from its trial of a new drug for heavily pretreated patients with metastatic prostate cancer. After 12 weeks… [Read More]
December 02, 2024
Delcath Systems Green-Lit by FDA for Phase 2 Trial in Liver-Dominant Metastatic Colorectal Cancer
Delcath Systems, Inc. (NASDAQ: DCTH), a company specializing in interventional oncology, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New… [Read More]
November 29, 2024
Silo Pharma Enters Joint Development Agreement for Ketamine Implant Device Targeting Pain Management
Silo Pharma, Inc. (Nasdaq: SILO), a developmental biopharmaceutical company focused on innovative therapeutics and drug delivery systems, has entered into a collaboration with Kymanox to… [Read More]
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for SAN711, a first-in-class, highly selective GABA A… [Read More]
November 26, 2024
Biotech M&A: Poseida Therapeutics Acquired By Roche Holdings, Stock Surges Over 200%
Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage company specializing in allogeneic cell therapy and genetic medicines for cancer, autoimmune, and rare diseases, announced today that… [Read More]
November 25, 2024
The Department of Government Efficiency (DOGE): A Potential Game-Changer for Biotech
The Department of Government Efficiency (DOGE), launched by Donald Trump in collaboration with Elon Musk and Vivek Ramaswamy, aims to overhaul federal operations, with a… [Read More]
Cassava Sciences (NASDAQ: SAVA) shares fell sharply on Monday, dropping 84% following the release of Phase 3 trial results for its Alzheimer’s drug, Simufilam. The… [Read More]
November 22, 2024
Biotech Meets Bitcoin: Anixa Biosciences Embraces Cryptocurrency to Bolster Treasury Strategy
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company advancing cancer treatments and prevention, announced its Board of Directors has approved the purchase of Bitcoin as… [Read More]
November 21, 2024
Lipella Pharmaceuticals Completes Dosing of First Cohort in Phase 2a Trial of LP-310; Top-Line Data Expected by Year-End
Today the clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, Lipella Pharmaceuticals Inc. (LIPO) announced the completion of dosing… [Read More]